Published in Clin Cancer Res on June 01, 1997
The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A (2003) 1.80
GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol (2004) 1.77
Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol (1998) 1.06
Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg (2007) 1.05
Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis. J Biol Chem (2013) 0.92
Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J Immunol (2010) 0.89
Cytokine-induced tumor suppressors: a GRIM story. Cytokine (2010) 0.88
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) (2009) 0.87
GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring. Oncogene (2009) 0.87
Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels. Am J Pathol (2007) 0.86
GRIM-19 and p16(INK4a) synergistically regulate cell cycle progression and E2F1-responsive gene expression. J Biol Chem (2010) 0.84
Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo. J Interferon Cytokine Res (2009) 0.83
Identification of a structural motif in the tumor-suppressive protein GRIM-19 required for its antitumor activity. Am J Pathol (2010) 0.81
Identification and characterization of GRIM-1, a cell-death-associated gene product. J Cell Sci (2010) 0.79
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics. Mol Cancer Ther (2010) 0.78
GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis. Oncogene (2013) 0.77
GRIM-19: A Double-edged Sword that Regulates Anti-Tumor and Innate Immune Responses. Transl Oncogenomics (2008) 0.76
GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism. Cytokine Growth Factor Rev (2016) 0.75
Mitochondrial GRIM-19 as a potential therapeutic target for STAT3-dependent carcinogenesis of gastric cancer. Oncotarget (2016) 0.75
DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma. Cancer Med (2017) 0.75
GRIM-19 Expression and Function in Human Gliomas. J Korean Neurosurg Soc (2010) 0.75
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene. Mol Cell Biol (1994) 2.63
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem (2000) 2.08
Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07
Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem (2001) 2.07
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene (2006) 1.78
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47
ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. J Biol Chem (2001) 1.44
RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response. J Biol Chem (2000) 1.43
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem (2000) 1.38
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38
The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Gene induction by interferons: functional complementation between trans-acting factors induced by alpha interferon and gamma interferon. Mol Cell Biol (1990) 1.32
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
CCAAT/enhancer-binding protein-beta regulates interferon-induced transcription through a novel element. J Biol Chem (2000) 1.15
Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. Infect Immun (1999) 1.15
An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest (1996) 1.14
Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09
Interferon gamma-induced transcription of the murine ISGF3gamma (p48) gene is mediated by novel factors. Proc Natl Acad Sci U S A (1997) 1.08
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08
Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol (1998) 1.06
Transcriptional repression of interleukin-6 gene by adenoviral E1A proteins. J Biol Chem (1992) 1.06
Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J Immunol (1978) 1.05
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05
Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res (1992) 1.04
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. Nat New Biol (1971) 1.03
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene (2007) 1.03
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med (1992) 1.03
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem (1996) 1.02
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst (1989) 1.02
Mechanistic studies of polyene enhancement of interferon production by polyriboinosinic-polyribocytidylic acid. Antimicrob Agents Chemother (1978) 1.01
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res (1993) 0.99
The effect of interferon on the metabolism of LDLs. Arterioscler Thromb (1992) 0.98
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res (1990) 0.98
Studies on the poxvirus Cotia. J Gen Virol (1980) 0.97
Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha. J Interferon Res (1985) 0.97
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer (1978) 0.97
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene (2012) 0.96
The polyoma virus T antigen interferes with interferon-inducible gene expression. Proc Natl Acad Sci U S A (1998) 0.96
Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol (1994) 0.96
Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem (1997) 0.96
Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res (1989) 0.94
Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res (1997) 0.93
2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals. AIDS (1991) 0.93
An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod (1985) 0.93
Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest (1985) 0.93
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest New Drugs (1990) 0.92
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer (2011) 0.91
The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein. J Immunol (1975) 0.91
Interferons: biochemical, cell growth inhibitory, and immunological effects. Prog Hematol (1981) 0.91
Interferons: rationale for clinical trials in neoplastic disease. Ann Intern Med (1979) 0.90
GRIM-19 associates with the serine protease HtrA2 for promoting cell death. Oncogene (2007) 0.90
Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. Cancer Gene Ther (2010) 0.90
Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol (1992) 0.90
Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J Immunother Emphasis Tumor Immunol (1993) 0.89
Induction of interferon synthesis and activation of interferon-stimulated genes by liposomal transfection reagents. J Interferon Cytokine Res (1998) 0.89
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene (2011) 0.89
Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer (1997) 0.88
GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring. Oncogene (2009) 0.87
Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol Cell Biochem (1997) 0.87
The interferon-inducible murine p48 (ISGF3gamma) gene is regulated by protooncogene c-myc. Proc Natl Acad Sci U S A (1997) 0.87
Effects of amphotericin B and its methyl ester on the antiviral activity of polyinosinic:polycytidylic acid. Antimicrob Agents Chemother (1979) 0.87
Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther (1997) 0.87
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol (1987) 0.87
Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines. J Urol (1991) 0.87
Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res (1989) 0.87
Comparison of agar and agarose preparations for mengovirus plaque formation. Appl Microbiol (1970) 0.86
Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol (1983) 0.86
Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res (2000) 0.86
Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells. J Immunol (1984) 0.86
Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. Cancer Res (1984) 0.86
Progress toward therapeutic application of interferons, 1979-1983. Cancer (1984) 0.85